



EDAP Installs Third Sonolith i-move in the United States

LYON, France, April 26, 2012 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), a global leader in therapeutic ultrasound, announced today the installation of a third Sonolith i-move lithotripter in the U.S. The revolutionary lithotripter has been delivered to Allied Metro, a New York tri-state area partnership with more than 300 urologists.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We are pleased to have completed the delivery and installation of the third Sonolith i-move, as we had previously announced that this unit was in our sales backlog. The device was purchased by one of the largest and strongest urology partnerships in the New York metro area and, with more than 300 physicians, Allied Metro is clearly a leading and national reference group in Lithotripsy."

Jon Owen Marks, MD, Allied Metro's Chief Executive Officer, remarked, "We were impressed with the Sonolith i-move during our demonstration trial last year. It continues to receive excellent reviews from our physicians and technologists now that it has been put into service at one of our surgical sites earlier this month. The vastly superior integration of ultrasound localization on the Sonolith i-move is a clear advantage compared to other lithotripters currently available on the market."

Mr. Oczachowski concluded, "Our Sonolith i-move device is a real-time, 3D lithotripter that is well suited for urology practices that are seeking a modular machine with significant power to treat urinary stones. We are conducting product demonstrations across the country and maintaining an active sales presence at medical meetings, including the upcoming American Urology Association's annual meeting that will be held in mid-May in Atlanta."

Sonolith i-move is a compact lithotripter with a revolutionary infrared stereo-vision system for real-time, three-dimensional ultrasound localization of urinary stones. With its various modular configurations, Sonolith i-move will replace Sonolith Praktis, an earlier generation lithotripter, and complements the Company's high-end Sonolith I-sys lithotripter, an integration of x-ray and ultrasound localization systems. Sonolith i-move received European (CE) approval in April 2010, Japanese approval in June 2011 and U.S. marketing clearance in August 2011.

About Allied Metro

Allied Metro is dedicated to providing the most advanced technology to relieve the pain and discomfort of kidney stones and to treat other urological disorders. Recognized as the leaders in urology treatments in New York since 1988, the partnership is the New York metropolitan area's largest, most experienced provider of shock wave lithotripsy. In addition, they offer therapy for Benign Prostatic Hyperplasia, cryosurgery for prostate cancer, and a growing array of other outpatient urological services. The practice encompasses ten AAAHC-accredited office based surgical sites located throughout the New York metropolitan area. Affiliated urologists rely on state-of-art equipment and expert clinical personnel to annually treat over 6,000 patients for kidney stones at modern facilities and area hospitals — more than any other single organization in the New York metropolitan area. Allied Metro's urology equipment and clinical personnel provide mobile services to over 30 hospitals in the New York tri-state area.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm®, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, and <http://www.hifu-planet.com>.

CONTACT: Blandine Confort

EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

Investors:

Stephanie Carrington

The Ruth Group

646-536-7017

scarrington@theruthgroup.com

Source: EDAP TMS SA

News Provided by Acquire Media